Balch Hill Capital’s Catheter Precision VTAK Stock Holding History

Balch Hill Capital’s Portfolio VTAK Stock Details VTAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2	Closed	-$565K	–	2
2019 Q4	$565K	Buy	+2	New	+$609K	2.48%	2

Other funds holding VTAK

ACM

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BLAM

Bourne Lent Asset Management Pawling, New York $289M AUM 30.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Weil Company San Diego, California $445M AUM 14.95% 1-Year Est. Return

SWM

Sculati Wealth Management Bloomfield Hills, Michigan $300M AUM 17.56% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balch Hill Capital's VTAK Position: Q1 2020 in Review

Balch Hill Capital sold out of Catheter Precision (VTAK) in Q1 2020, closing a stake of 2 shares — an estimated $565K sold.

Balch Hill Capital first reported a position in VTAK in Q4 2019 and held it in 1 quarter. The position peaked at $565K in Q4 2019. 5 funds tracked by Wall St. Rank hold VTAK as of Q1 2020.

Balch Hill Capital reported no remaining Catheter Precision position as of Q1 2020 after selling out during the quarter.
Balch Hill Capital sold 2 Catheter Precision shares in Q1 2020, an estimated $565K.
Balch Hill Capital first reported a position in Catheter Precision in Q4 2019 and held it in 1 quarter.
Balch Hill Capital's Catheter Precision position peaked at $565K in Q4 2019.
5 funds tracked by Wall St. Rank held Catheter Precision as of Q1 2020.

Based on Balch Hill Capital's 13F filing for Q1 2020.